US FDA Panel Weighs Design Of A Pre-approval Safety Study For Janssen's Sirukumab

IL-6 inhibitor should be compared to another biologic to exclude a multi-fold increase in the risk of death, advisers say; FDA assures the panel's industry representative it is not considering an across-the-board requirement for large safety studies of rheumatoid arthritis treatments.